Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 1-Year High - Should You Buy?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report)'s stock price reached a new 52-week high on Friday . The company traded as high as $306.00 and last traded at $304.55, with a volume of 1387501 shares. The stock had previously closed at $292.90.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ALNY shares. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $280.00 to $328.00 in a report on Monday, March 24th. Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective for the company. Finally, Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Up 4.0%

The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a market cap of $39.71 billion, a P/E ratio of -140.36 and a beta of 0.17. The stock has a 50-day moving average of $260.38 and a 200 day moving average of $254.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Capital World Investors grew its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after acquiring an additional 323,206 shares during the last quarter. Capital Research Global Investors grew its position in Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after acquiring an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after acquiring an additional 33,696 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.